Print this Page
E-mail This Page
Veda N Giri, MD
Medical Oncology
Director, Prostate Cancer Risk Assessment Program
Meet other members of the prostate cancer treatment team.
Meet other members of the breast cancer treatment team.
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111-2497
To make an appointment, call:
215-728-2570.
For general information, call:
1-888-FOX CHASE.
An oncology certified nurse will assist you.
Clinical Expertise:
Breast Cancer; Prostate Cancer; Cancer Genetics
Medical Education:
Jefferson Medical College, Philadelphia, Pa., 1997
Residency:
Internal Medicine, University of Michigan Medical Center, Ann Arbor, Mich.
Fellowship:
Hematology-Oncology, University of Michigan Medical Center, Ann Arbor, Mich.
Certifications:
American Board of Internal Medicine;
Medical Oncology
Professional Societies:
American Society of Clinical Oncology;
American Association for Cancer Research;
American Society of Preventive Oncology
Scientific Report:
Medical Oncology: Clinical Trials Research;
DNA Repair of Mismatched Bases and Early Molecular Changes in Tumorigenesis;
The Prostate Cancer Risk Assessment Program
(These links require Adobe® Acrobat Reader to view.)
Research Interests:
I believe that patients receive the best care by having a comprehensive evaluation in a receptive and understanding environment. With my background in medical oncology and translational cancer research, I am able to provide a unique experience to my patients with regard to the evaluation and treatment of cancer.
I joined the staff of Fox Chase in 2004. Since that time, I have been named the director of the Prostate Cancer Risk Assessment Program. I was appointed to the National Institutes of Health Prostate Cancer Genetics PDQ Editorial Board. At Fox Chase, I am an active member of the IRB (Institutional Review Board) as well as the Executive Steering Committee.
The American Cancer Society awarded me the Special Interest Award to investigate the role of DNA mismatch repair defects in prostate cancer susceptibility. In the laboratory, I perform ongoing research into the genetic, molecular and proteomic pathways involved in cancer susceptibility, especially prostate cancer.